{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:41:32Z","timestamp":1792201292190,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.vaccine.2017.07.016","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T05:30:42Z","timestamp":1500096642000},"page":"4569-4577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"PB","title":["Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice"],"prefix":"10.1016","volume":"35","author":[{"given":"T\u00fclin","family":"Mor\u00e7\u04e7l","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Bart","family":"Tarbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.07.016_b0005","unstructured":"Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication. In: Knipe DM Howley PM, Eds. Fields Virology, 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins. 2007;1647\u20131689."},{"key":"10.1016\/j.vaccine.2017.07.016_b0010","unstructured":"Cox NJ, Neumann G, Donis RO, Kawaoka Y (2005) Orthomyxoviruses: influenza. Mahy BWJ, ter Meulen V, Eds. Topley and Wilson\u2019s microbiology and microbial infections. London: Hodder Arnold Press. 2005;634\u2013698."},{"key":"10.1016\/j.vaccine.2017.07.016_b0015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nature06945","article-title":"The genomic and epidemiological dynamics of human influenza A virus","volume":"45","author":"Rambaut","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.07.016_b0020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nature04230","article-title":"Characterization of the 1918 influenza virus polymerase genes","volume":"437","author":"Taubenberger","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.07.016_b0025","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature08157","article-title":"Emergence and pandemic potential of swine-origin H1N1 influenza virus","volume":"459","author":"Neumann","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.07.016_b0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.micinf.2009.05.002","article-title":"April 2009: an outbreak of swine-origin influenza A (H1N1) virus with evidence for human-to-human transmission","volume":"11","author":"Naffakh","year":"2009","journal-title":"Microbes Infect"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.07.016_b0035","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/cid\/ciq012","article-title":"Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010)","volume":"52","author":"Shrestha","year":"2011","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2017.07.016_b0040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1473-3099(12)70121-4","article-title":"Estimated global mortality associated with the first 12months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study","volume":"12","author":"Dawood","year":"2012","journal-title":"Lancet-Infect Diseas"},{"key":"10.1016\/j.vaccine.2017.07.016_b0045","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/39218","article-title":"A pandemic warning?","volume":"389","author":"de Jong","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.07.016_b0050","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2017.07.016_b0055","unstructured":"CDC. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Report 2009;58:521\u2013524."},{"key":"10.1016\/j.vaccine.2017.07.016_b0060","unstructured":"World Health Organization (WHO). Influenza pandemic preparedness and response. Available from: http:\/\/www.who.int\/csr\/disease\/swineflu\/notes\/pandemic_influenza_vaccines_20090924\/en\/."},{"key":"10.1016\/j.vaccine.2017.07.016_b0065","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1016\/j.vaccine.2016.08.019","article-title":"The 2015 global production capacity of seasonal and pandemic influenza vaccine","volume":"34","author":"McLean","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.016_b0070","unstructured":"Technical Advisory Group on Vaccine-Preventable Diseases. Final Recommendations of Pandemic Influenza. Pan American Health Organization, Regional Office of the World Health Organization (2009). Available at: http:\/\/www.paho.org\/english\/ad\/fch\/im\/PandemicFlu_TAGReco_Aug2009_ e.pdf."},{"key":"10.1016\/j.vaccine.2017.07.016_b0075","unstructured":"FDA Workshop on adjuvants and adjuvanted preventive and therapeutic vaccines, December 2. 2008. http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/newsevents\/workshopsmeetingsconferences\/ucm095708.pdf."},{"key":"10.1016\/j.vaccine.2017.07.016_b0080","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1586\/erv.10.141","article-title":"Monovalent inactivated split-virion, AS03-adjuvanted pandemic influenza A (H1N1) vaccine","volume":"9","author":"Walker","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.07.016_b0085","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1086\/507544","article-title":"Vaccines for seasonal and pandemic influenza","volume":"194","author":"Nichol","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.016_b0090","unstructured":"FDA Press Release, http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm182399.htm, Sep. 15, 2009."},{"key":"10.1016\/j.vaccine.2017.07.016_b0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(09)62026-2","article-title":"Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomized controlled phase 2 trials","volume":"375","author":"Plennevaux","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.07.016_b0100","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1056\/NEJMoa0908535","article-title":"A novel influenza A (H1N1) vaccine in various age groups","volume":"361","author":"Zhu","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.016_b0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.1911","article-title":"Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial","volume":"303","author":"Nolan","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.07.016_b0110","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1097\/INF.0b013e318257644f","article-title":"Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A\/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children","volume":"31","author":"Block","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.07.016_b0115","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2017.07.016_b0120","doi-asserted-by":"crossref","first-page":"e1161","DOI":"10.1542\/peds.2010-1920","article-title":"Influenza A\/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 Months","volume":"127","author":"Esposito","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.07.016_b0125","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1086\/655830","article-title":"AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85years of age","volume":"51","author":"Roman","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.016_b0130","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1016\/j.vaccine.2010.06.065","article-title":"Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6\u201335months","volume":"28","author":"Carmona","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.016_b0135","first-page":"15","article-title":"breakthrough infections and estimates of vaccine effectiveness in Germany 2009\u20132010","volume":"2010","author":"Wichmann","year":"2009","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2017.07.016_b0140","unstructured":"FDA News release: FDA Approves first seasonal influenza vaccine containing an adjuvant. November 24, 2015. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm474295.htm."},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.016_b0145","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/erv.10.36","article-title":"Current controversies in the USA regarding vaccine safety","volume":"9","author":"Chatterjee","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.07.016_b0150","unstructured":"Bell SJD, Morcol T, He Q, Therapeutic calcium phosphate particles and methods of manufacture and use, US Patent 6,355,271 (2002)."},{"key":"10.1016\/j.vaccine.2017.07.016_b0155","unstructured":"Bell SJD, Morcol T, He Q. Therapeutic calcium phosphate particles and methods of manufacture and use. US Patent 8,431,221."},{"key":"10.1016\/j.vaccine.2017.07.016_b0160","unstructured":"Morcol T, Nagappan P, Nerenbaum L, Mitchel AR, Bell SJD. Particulate drug delivery systems for protein drugs In: Particlute Drug Delivery Volume 2, Ed. Kumar R., American Scientific Publishers, Stevenson Ranch, CA. 2008;Chapter 11:223-241."},{"key":"10.1016\/j.vaccine.2017.07.016_b0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/ps050209","article-title":"Evaluation of Novel particles as pulmonary delivery system for insulin in rats","volume":"5","author":"Garcia-Contreras","year":"2003","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.vaccine.2017.07.016_b0170","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/CDLI.7.6.899-903.2000","article-title":"Calcium phosphate nanoparticle adjuvant","volume":"6","author":"He","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.07.016_b0175","first-page":"1021","article-title":"Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2","volume":"9","author":"He","year":"2002","journal-title":"Clin Diagnos Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.07.016_b0180","unstructured":"Karam HM, Shaaban EA, Mohamed AF, Zaki HF, Kenawy SA. New approach for improving production for naja haje snake venom. Int J Sci Res Pub 2015;5 (3)."},{"key":"10.1016\/j.vaccine.2017.07.016_b0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vetmic.2009.05.004","article-title":"Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1\u20133CD gene construct protects mice and guinea pigs against the challenge virus","volume":"139","author":"Joyappa","year":"2009","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2017.07.016_b0190","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1637\/10510-020413-Reg.1","article-title":"Adjuvant effects of chitosan and calcium phosphate particles in an inactivated newcastle disease vaccine","volume":"58","author":"Volkova","year":"2014","journal-title":"Avian Diseases"},{"key":"10.1016\/j.vaccine.2017.07.016_b0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/1547691X.2013.772267","article-title":"Comparison of the adjuvant activity of aluminum hydroxide and calcium phosphate on the antibody response towards Bothrops asper snake venom","volume":"11","author":"Olmedo","year":"2014","journal-title":"J Immunotox"},{"key":"10.1016\/j.vaccine.2017.07.016_b0200","unstructured":"Morcol T, Philip R, Karabudak A, Huang X. Novel Calcium Phosphate Nanoparticle (CaPNP) Vaccine Adjuvant and Delivery System. Oral presentation at New Technologies New Vaccines 2015, Wilmington DE, 2015;March 22-25. http:\/\/www.ntnv.org\/wp-content\/uploads\/2016\/12\/1600-Morcol.pdf."},{"key":"10.1016\/j.vaccine.2017.07.016_b0205","doi-asserted-by":"crossref","unstructured":"Huang X, Karabudak A, Comber J, Morcol T, Philip R. Novel vaccination approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles. Submitted to Human Vaccines Immotherapeutics; Nov. 2016.","DOI":"10.1080\/21645515.2017.1369639"},{"key":"10.1016\/j.vaccine.2017.07.016_b0210","doi-asserted-by":"crossref","first-page":"8607","DOI":"10.1128\/JVI.00159-10","article-title":"Adaptation of Pandemic H1N1 Influenza Viruses in Mice","volume":"84","author":"Ilyushina","year":"2010","journal-title":"J Virology"},{"key":"10.1016\/j.vaccine.2017.07.016_b0215","first-page":"e220928","article-title":"Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 Pandemic H1N1 Influenza in Mice","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.07.016_b0220","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.vaccine.2012.06.041","article-title":"Vaccine production training to develop the workforce of foreign institutions supported by the BARDA influenza vaccine capacity building program","volume":"31","author":"Tarbet","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.016_b0225","unstructured":"Morcol T, Dell A, Lieb L, CaP Adjuvant Enhances Th1 and Th2 Response to a Single\/Low Dose Inactivated 2009 Pandemic H1N1 Virus Vaccine. Poster session presented at: Adjuvants & Delivery Systems. Immunotherapeutics and Vaccine Summit (ImVacS), 2010 August 17-19; Cambridge MA. Selected data in \u201cSupplementary Material\u201d."},{"key":"10.1016\/j.vaccine.2017.07.016_b0230","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1128\/CVI.00449-10","article-title":"Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus","volume":"18","author":"Papenburg","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.07.016_b0235","first-page":"385","article-title":"Calcium phosphate adjuvanted allergens: Total and specific IgE levels before and after immunotherapy with house dust and mite extracts","volume":"134D","author":"Ickovic","year":"1983","journal-title":"Ann Immunol"},{"key":"10.1016\/j.vaccine.2017.07.016_b0240","doi-asserted-by":"crossref","unstructured":"Kato H, Shibamo M, Relationship between hemolytic activity and absorption capacity of aluminum and calcium phosphate as immunological adjuvants for biologicals. Microbio.l Immunol. 1994 (38) 543-548.","DOI":"10.1111\/j.1348-0421.1994.tb01820.x"},{"key":"10.1016\/j.vaccine.2017.07.016_b0245","first-page":"131","article-title":"Preparation and use of calcium phosphate adsorbed vaccines","volume":"65","author":"Relyveld","year":"1986","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2017.07.016_b0250","series-title":"Vaccinia, vaccination, vaccinology","first-page":"95","article-title":"A history of toxoids","author":"Relyveld","year":"1996"},{"key":"10.1016\/j.vaccine.2017.07.016_b0255","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nature Med"},{"key":"10.1016\/j.vaccine.2017.07.016_b0260","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0264-410X(96)00287-3","article-title":"Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants","volume":"15","author":"Benne","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.016_b0265","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1086\/314952","article-title":"Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection","volume":"180","author":"Moran","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.016_b0270","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/CVI.00156-06","article-title":"Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza","volume":"13","author":"Huber","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.07.016_b0275","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-3083.2005.01633.x","article-title":"Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB\/c mice","volume":"62","author":"Hovden","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2017.07.016_b0280","first-page":"707","article-title":"Overview of Serological techniques for influenza vaccine evaluation: past","volume":"2","author":"Trombetta","year":"2014","journal-title":"Present Future Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2017.07.016_b0285","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00430-010-0143-4","article-title":"Determination of serum antibodies against swine origin influenza A virus H1N1\/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?","volume":"199","author":"Allwinn","year":"2010","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.07.016_b0290","doi-asserted-by":"crossref","unstructured":"Zhou W, Mogucheb AO, Chiua D, Murali-Krishna K, Baneyx F. Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8+ T cell responses in mice. Nanomedicine: Nanotech Biol Med 2014;10:571\u2013578.","DOI":"10.1016\/j.nano.2013.11.007"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730912X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730912X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T10:36:13Z","timestamp":1602498973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1730912X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":58,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0264410X1730912X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}